{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:32:37Z","timestamp":1787563957771,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81630105"],"award-info":[{"award-number":["81630105"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2019YFC1708600, 2019YFC17086003"],"award-info":[{"award-number":["2019YFC1708600, 2019YFC17086003"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013115","name":"Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents","doi-asserted-by":"publisher","award":["2019R51002"],"award-info":[{"award-number":["2019R51002"]}],"id":[{"id":"10.13039\/501100013115","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stable angina pectoris (SAP) currently seriously threatens the health of humans, and mortality is continuously rising. Current treatment strategies mainly include pharmaceutical therapy and revascularization. In China, Buyang Huanwu granules (BYHW) and Naoxintong capsules (NXT) have been used in the treatment of SAP, but it is not clear which agent is better in terms of relieving symptoms and improving quality of life. Therefore, we designed a clinical trial to compare the efficacy and safety of NXT and BYHW in the treatment of SAP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a randomized, blinded, parallel controlled, multicentre clinical trial protocol. On the basis of standardized Western medicine treatment, a total of 128 SAP patients will be randomly divided into intervention group 1 (NXT group), intervention group 2 (BYHW group), and a control group (placebo group) at a 2:1:1 ratio. A 2-week run-in period is required prior to randomization, and a 1-week baseline period and 4-week treatment period are included in this study. The primary outcome is the efficacy rate of stable angina symptom score improvement; the secondary outcomes include the effect on electrocardiograms, Seattle Angina Questionnaire scores, and nitroglycerine consumption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study will evaluate the efficacy and safety of NXT and BYHW in the treatment of SAP. The results will provide critical evidence for using Chinese herbal medicines to treat SAP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Chinese Clinical Trials Registry ChiCTR1800015191. Registered on 13 March 2018.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=25818\">http:\/\/www.chictr.org.cn\/showproj.aspx?proj=25818<\/jats:ext-link>\n                      . All the registration items can be found within the protocol.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-021-05914-1","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T04:04:16Z","timestamp":1642737856000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of Buyang Huanwu granules and Naoxintong capsules in the treatment of stable angina pectoris: rationale and design of a randomized, blinded, multicentre clinical trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiehong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"issue":"7","key":"5914_CR1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.hlc.2019.05.001","volume":"28","author":"A Palagyi","year":"2019","unstructured":"Palagyi A, de Silav HA, Praveen D, Patel A. Combatting the global crisis of cardiovascular disease. Heart Lung Circ. 2019;28(7):981\u20133. https:\/\/doi.org\/10.1016\/j.hlc.2019.05.001.","journal-title":"Heart Lung Circ."},{"issue":"1","key":"5914_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12992-021-00683-7","volume":"17","author":"MY Ma","year":"2021","unstructured":"Ma MY, Tian WX, Kang J, Li YZ, Xia Q, Wang NS, et al. Does the medical insurance system play a real role in reducing catastrophic economic burden in elderly patients with cardiovascular disease in China? Implication for accurately targeting vulnerable characteristics. Global Health. 2021;17(1):36. https:\/\/doi.org\/10.1186\/s12992-021-00683-7.","journal-title":"Global Health."},{"issue":"4","key":"5914_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41569-018-0119-4","volume":"16","author":"D Zhao","year":"2019","unstructured":"Zhao D, Liu J, Wang M, Zhang XG, Zhou MG. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16(4):203\u201312. https:\/\/doi.org\/10.1038\/s41569-018-0119-4.","journal-title":"Nat Rev Cardiol."},{"issue":"10","key":"5914_CR4","doi-asserted-by":"publisher","first-page":"16812","DOI":"10.1002\/jcp.28350","volume":"234","author":"AK Malakar","year":"2019","unstructured":"Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812\u201323. https:\/\/doi.org\/10.1002\/jcp.28350.","journal-title":"J Cell Physiol."},{"issue":"1","key":"5914_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4103\/ijpvm.IJPVM_347_18","volume":"10","author":"V Demir","year":"2019","unstructured":"Demir V, Yilmaz S, Ede H, Turan Y. Correlation of resting heart rate with the severity and complexity of coronary artery disease: a single-center retrospective study. Int J Prev Med. 2019;10(1):104. https:\/\/doi.org\/10.4103\/ijpvm.IJPVM_347_18.","journal-title":"Int J Prev Med."},{"key":"5914_CR6","volume-title":"Stable angina: management","author":"NICE","year":"2016","unstructured":"NICE. Stable angina: management. London: National Institute for Health and Care Excellence (UK); 2016. https:\/\/www.nice.org.uk\/guidance\/cg126"},{"issue":"12","key":"5914_CR7","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.je.2016.12.019","volume":"27","author":"DF Ma","year":"2017","unstructured":"Ma DF, Sakai H, Wakabayashi C, Kwon JS, Lee Y, Liu S, et al. The prevalence and risk factor control associated with noncommunicable diseases in China, Japan, and Korea. J Epidemiol. 2017;27(12):568\u201373. https:\/\/doi.org\/10.1016\/j.je.2016.12.019.","journal-title":"J Epidemiol."},{"issue":"4","key":"5914_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/FJC.0000000000000716","volume":"74","author":"D Farmakis","year":"2019","unstructured":"Farmakis D, Andrikopoulos G, Giamouzis G, Giannakoulas G, Poulimenos L, Skalidis E, et al. Practical recommendations for the diagnosis and medical management of stable angina: an expert panel consensus. J Cardiovasc Pharmacol. 2019;74(4):308\u201314. https:\/\/doi.org\/10.1097\/FJC.0000000000000716.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"4","key":"5914_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1161\/CIRCULATIONAHA.118.033484","volume":"138","author":"CX Shen","year":"2018","unstructured":"Shen CX, Ge JB. Epidemic of cardiovascular disease in China: current perspective and prospects for the future. Circulation. 2018;138(4):342\u20134. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.033484.","journal-title":"Circulation."},{"issue":"3","key":"5914_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehz425.","journal-title":"Eur Heart J."},{"issue":"1","key":"5914_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.15420\/ecr.2018.26.1","volume":"14","author":"TA Rousan","year":"2019","unstructured":"Rousan TA, Thadani U. Stable angina medical therapy management guidelines: a critical review of guidelines from the European society of cardiology and national institute for health and care excellence. Eur Cardiol. 2019;14(1):18\u201322. https:\/\/doi.org\/10.15420\/ecr.2018.26.1.","journal-title":"Eur Cardiol."},{"key":"5914_CR12","doi-asserted-by":"publisher","unstructured":"Yan D, Zhao LL, Yue BW, Qian H, Zhang ZH, Wang N, et al. Granule of BU-XIN RUAN-MAI attenuates the patients\u2019 angina pectoris of coronary heart disease via regulating miR-542-3p\/GABARAP signaling. Evid Based Complement Alternat Med. 2019;1808419:1\u201320. https:\/\/doi.org\/10.1155\/2019\/1808419.","DOI":"10.1155\/2019\/1808419"},{"issue":"09","key":"5914_CR13","first-page":"1469","volume":"19","author":"YC Zheng","year":"2021","unstructured":"Zheng YC, Lu WX, Lu N. Efficacy and safety of Buyang Huanwu Decoction in treating angina pectoris of coronary heart disease with Qi deficiency and blood stasis: a meta-analysis. Chin J Integr Med Cardio-Cerebrovasc Dis. 2021;19(09):1469\u201375.","journal-title":"Chin J Integr Med Cardio-Cerebrovasc Dis."},{"issue":"05","key":"5914_CR14","first-page":"717","volume":"19","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Bao XL, Wang D, Li P, Cui XF, Li JL. Systematic review of the efficacy and safety of Buyang Huanwu Decoction combined with conventional western medicine in the treatment of stable angina pectoris. Chin J Integr Med Cardio-Cerebrovasc Dis. 2021;19(05):717\u201324.","journal-title":"Chin J Integr Med Cardio-Cerebrovasc Dis."},{"issue":"3","key":"5914_CR15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s11655-018-2981-6","volume":"24","author":"LT Liu","year":"2018","unstructured":"Liu LT. Chinese experts consensus on clinical application of Naoxintong Capsule. Chin J Integr Med. 2018;24(3):232\u20136. https:\/\/doi.org\/10.1007\/s11655-018-2981-6.","journal-title":"Chin J Integr Med."},{"key":"5914_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.phrs.2019.01.024","volume":"141","author":"JH Han","year":"2019","unstructured":"Han JH, Tan H, Duan YJ, Chen YL, Zhu Y, Zhao BC, et al. The cardioprotective properties and the involved mechanisms of NaoXinTong Capsule. Pharmacol Res. 2019;141:409\u201317. https:\/\/doi.org\/10.1016\/j.phrs.2019.01.024.","journal-title":"Pharmacol Res."},{"issue":"09","key":"5914_CR17","doi-asserted-by":"publisher","first-page":"814","DOI":"10.13288\/j.11-2166\/r.2020.09.019","volume":"61","author":"J Wang","year":"2020","unstructured":"Wang J, Zhao T, Li J, Dong Y, Yang XC, Zhao C, et al. Overview on the clinical efficacy and action mechanism of Naoxintong Capsules in the treatment of coronary heart disease. J Tradit Chin Med. 2020;61(09):814\u20137. https:\/\/doi.org\/10.13288\/j.11-2166\/r.2020.09.019.","journal-title":"J Tradit Chin Med"},{"key":"5914_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.7661\/j.cjim.20170718.305","volume":"37","author":"LT Liu","year":"2017","unstructured":"Liu LT, Fu CG. \u2018Chinese Experts Consensus on Clinical Application of Naoxintong Capsule\u2019 compilation team. Chinese Experts Consensus on Clinical Application of Naoxintong Capsule. Chin J Integr Tradit West Med. 2017;37:1039\u201342. https:\/\/doi.org\/10.7661\/j.cjim.20170718.305.","journal-title":"Chin J Integr Tradit West Med"},{"key":"5914_CR19","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3389\/fphar.2020.00892","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang L, Pan YJ, Fu W, Huang SW, Xu B, et al. Investigation of invigorating Qi and activating blood circulation prescriptions in treating Qi deficiency and blood stasis syndrome of ischemic stroke patients: Study protocol for a randomized controlled trial. Front Pharmacol. 2020;11:892. https:\/\/doi.org\/10.3389\/fphar.2020.00892.","journal-title":"Front Pharmacol."},{"issue":"2","key":"5914_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/0976-500X.72352","volume":"1","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. Consort 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010;1(2):100\u20137. https:\/\/doi.org\/10.4103\/0976-500X.72352.","journal-title":"J Pharmacol Pharmacother."},{"issue":"9861","key":"5914_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0140-6736(12)62160-6","volume":"381","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Dickersin K, Moher D. Spirit 2013: new guidance for content of clinical trial protocols. Lancet. 2013;381(9861):91\u20132. https:\/\/doi.org\/10.1016\/S0140-6736(12)62160-6.","journal-title":"Lancet."},{"issue":"03","key":"5914_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3760\/j.issn:0253-3758.2007.03.002","volume":"35","author":"Chinese Society of Cardiology and Editorial board of Chinese Journal of Cardiology","year":"2007","unstructured":"Chinese Society of Cardiology and Editorial board of Chinese Journal of Cardiology. Guidelines for diagnosis and treatment of chronic stable angina pectoris. Chin J Cardiol. 2007;35(03):195\u2013206. https:\/\/doi.org\/10.3760\/j.issn:0253-3758.2007.03.002.","journal-title":"Chin J Cardiol."},{"issue":"1","key":"5914_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/s0735-1097(02)02848-6","volume":"41","author":"RJ Gibbons","year":"2003","unstructured":"Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC\/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the ACC\/AHA task force on practice guidelines (committee on the management of patients with chronic stable angina). J Am Coll Cardiol. 2003;41(1):159\u201368. https:\/\/doi.org\/10.1016\/s0735-1097(02)02848-6.","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"5914_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s11655-015-2040-6","volume":"21","author":"DP Xu","year":"2015","unstructured":"Xu DP, Wu HL, Lan TH, Wang X, Sheng XG, Lin Y, et al. Effect of Shenzhu Guanxin recipe on patients with angina pectoris after percutaneous coronary intervention: a prospective, randomized controlled trial. Chin J Integr Med. 2015;21(6):408\u201316. https:\/\/doi.org\/10.1007\/s11655-015-2040-6.","journal-title":"Chin J Integr Med."},{"key":"5914_CR25","volume-title":"Guideline for clinical trials of new patent Chinese medicines (trial implementation)","author":"XY Zheng","year":"2002","unstructured":"Zheng XY. Guideline for clinical trials of new patent Chinese medicines (trial implementation). Beijing: China Medical Science and Technology Press; 2002."},{"issue":"5","key":"5914_CR26","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1161\/CIRCOUTCOMES.114.000967","volume":"7","author":"PS Chan","year":"2014","unstructured":"Chan PS, Jones PG, Arnold SA, Spertus JA. Development and validation of a short version of the Seattle angina questionnaire. Circ Cardiovasc Qual Outcomes. 2014;7(5):640\u20137. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.114.000967.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"1","key":"5914_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12906-020-03174-1","volume":"21","author":"F Qu","year":"2021","unstructured":"Qu F, Zhang Q, Dai MC, He YJ, Wu JQ, Zhang X, et al. An evaluation survey of traditional Chinese medicine learning among international students majoring in conventional medicine: a study from a university in China. BMC Complement Med Ther. 2021;21(1):16. https:\/\/doi.org\/10.1186\/s12906-020-03174-1.","journal-title":"BMC Complement Med Ther."},{"key":"5914_CR28","doi-asserted-by":"publisher","unstructured":"Wang Q, Gu HM, Zhu JZ, Xu HJ, Xu YH. Clinical study on Buyang Huanwu decoction in the treatment of coronary heart disease angina pectoris of Qi deficiency and blood stasis type. J Nanjing Univ Tradit Chin Med. 2017;33(6):579\u201382. https:\/\/doi.org\/10.14148\/j.issn.1672-0482.2017.0579.","DOI":"10.14148\/j.issn.1672-0482.2017.0579"},{"issue":"2","key":"5914_CR29","doi-asserted-by":"publisher","first-page":"e017831","DOI":"10.1161\/JAHA.120.017831","volume":"10","author":"K Hao","year":"2021","unstructured":"Hao K, Takahashi J, Kikuchi Y, Suda A, Sato K, Sugisawa J, et al. Prognostic impacts of comorbid significant coronary stenosis and coronary artery spasm in patients with stable coronary artery disease. J Am Heart Assoc. 2021;10(2):e017831. https:\/\/doi.org\/10.1161\/JAHA.120.017831.","journal-title":"J Am Heart Assoc."},{"issue":"12","key":"5914_CR30","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.14009\/j.issn.1672-2124.2019.12.023","volume":"19","author":"CX Li","year":"2019","unstructured":"Li CX, Chen YH, Li XL, Tang JF, Zhang ML, Xu T, et al. Systematic review on efficacy and safety of Naoxintong capsules in the treatment of angina pectoris. Eval Anal Drug-Use Hosp Chin. 2019;19(12):1494\u20139. https:\/\/doi.org\/10.14009\/j.issn.1672-2124.2019.12.023.","journal-title":"Eval Anal Drug-Use Hosp Chin."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05914-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05914-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05914-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T04:06:23Z","timestamp":1642737983000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05914-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["5914"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05914-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"21 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The whole study process, the study protocol, and informed consent were approved by the Research Ethics Committee of the Second Affiliated Hospital of Zhejiang Chinese Medical University (approval number 2017-Y-070-01), and the Ethics Committee of Affiliated Hospital of Shanxi Chinese Medical University (approval number: 201902038). Written informed consent to participate will be obtained from all study participates.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participant"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}